NervGen Pharma Corp. (NGEN)
Develops drugs to repair nerve and spinal cord damage from injury and disease
$1.61-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-34.6%
The outlook
NGEN trades near its 52-week low, well below both its 50- and 200-day moving averages. Analysts lean strongly bullish with an average price target implying significant upside from current levels, though the stock remains under pressure. The neutral overall score reflects the disconnect between analyst sentiment and recent price action.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Price targetAvg target +559% vs current price
Analyst price target
~12-month · 7 analysts$10.60average target+558.7% vs now
Now $1.61
Low $5.03High $18.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$171.3M
52-wk high
$6.30
52-wk low
$1.59
50-day avg
$2.13
200-day avg
$3.50
Trailing P/E
—